Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) General Counsel Natalie Anne Marie Furney sold 30,868 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $527,842.80. Following the transaction, the general counsel directly owned 204,298 shares of the company’s stock, valued at approximately $3,493,495.80. This trade represents a 13.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.3%

Shares of NYSE TAK traded down $0.06 during trading on Wednesday, reaching $17.42. The company had a trading volume of 2,004,364 shares, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 12-month low of $12.99 and a 12-month high of $18.90. The stock has a market cap of $55.82 billion, a PE ratio of 51.24 and a beta of -0.08. The business’s 50-day moving average is $16.49 and its 200 day moving average is $17.13. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The firm had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. As a group, equities analysts forecast that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TAK. Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently bought and sold shares of TAK. Private Trust Co. NA boosted its holdings in shares of Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares during the period. SHP Wealth Management bought a new position in Takeda Pharmaceutical during the fourth quarter valued at approximately $42,000. Caitong International Asset Management Co. Ltd grew its position in Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.